Piper Sandler raised the firm’s price target on Veeva (VEEV) to $290 from $280 and keeps an Overweight rating on the shares following Q3 results. The firm cited “solid execution” and increasing adoption intent across the “Top 20” biopharma firms for the price target raise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV: